Samsung Life Science Fund Invests $15 Million in US Nanoparticle Drug Delivery Developer 'Senda'
Next-Generation Technology Overcoming Existing mRNA Limitations
Expected Alternative Treatments for Autoimmune Diseases and Cancer
[Asia Economy Reporter Lee Gwan-ju] Samsung is investing in the U.S. biotech company Senda Biosciences, which possesses drug delivery technology based on natural nanoparticles, and is taking steps to foster core technologies for next-generation biopharmaceuticals.
Life Science Fund (SVIC 54 New Technology Investment Association), established by Samsung C&T Corporation and Samsung Biologics, announced on the 17th that it will invest $15 million (approximately 19 billion KRW) in Senda.
Senda is a company formed by merging four natural nanoparticle research and development specialized companies invested in by Flagship Pioneering. It possesses platform technology that applies artificial intelligence and machine learning to millions of nanoparticle big data found in plants, animals, and bacteria to create optimized drug delivery systems. Based on this, it is developing new messenger RNA (mRNA) vaccines and therapeutic drugs. Flagship Pioneering, founded in 2000, is a U.S. healthcare-focused venture capital firm known for founding Moderna, which developed the COVID-19 vaccine.
Senda’s nanoparticle development technology enables efficient drug delivery to specific cells and tissues and can be applied to nucleic acids, gene editing, proteins, and peptides, offering alternatives for autoimmune diseases, metabolic disorders, and cancer treatments. Samsung plans to expand collaboration into various fields as the development of new biopharmaceutical pipelines applying Senda’s technology accelerates.
Hot Picks Today
If You’re Worried About Market Swings: "Steady Cash Flow Even Amid Volatility" - Experts Recommend These ETFs
- No Bacteria Detected in Arisu After 24 Hours of Repeated Drinking from a Tumbler
- "We Can't Just Let Them Be Damaged Inside"... Samsung Electronics Removes 360,000 Wafers in Preparation for Strike
- Wife in $6.7 Million Debt Took Out $3 Million in Husband's Life Insurance, Poisoned Him... US Court: "She Can Never Be Released"
- "He's Handsome, It's Such a Pity?"... Lawyer Responds to Bizarre 'Appearance Evaluation' of High School Girl Murder Suspect
Through the Life Science Fund, Samsung plans to continue discovering promising technologies and investing in innovative domestic and international venture companies with the goals of 'fostering global core bio technologies' and 'improving quality of life.' The Life Science Fund, established by Samsung C&T Corporation and Samsung Biologics in July last year with a scale of 150 billion KRW, made its first investment in March this year in the U.S. gene therapy development company Jaguar Gene Therapy.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
